Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Insider transactions by Patrick R. O'Neil, EVP, CLO & General Counsel at Ionis Pharmaceuticals (IONS). On 10/06/2025 the reporting person exercised 10,200 non‑qualified stock options with an exercise price of $52.87 and immediately sold those shares under a Rule 10b5‑1 plan. The Form 4 reports two separate block sales that day: 10,200 shares sold at a weighted average price of $69.8872 and 3,241 shares sold at a weighted average price of $69.2651, reflecting multiple executions within disclosed price ranges.
Following these transactions the reporting person’s beneficial ownership of common stock declined from 67,330 shares to 53,889, and the number of options/derivative securities held after the activity is reported as 17,000 exercisable into common stock. The sales were made pursuant to a 10b5‑1 trading plan adopted on 05/02/2025, and the filer offers to provide transaction‑level price details on request.
Brett P. Monia, Chief Executive Officer and Director of Ionis Pharmaceuticals (IONS), reported a sale of common stock under a pre-established Rule 10b5-1 trading plan. The report shows 437 shares were sold on 10/06/2025 at $69.2637 per share, leaving the reporting person with 179,572 shares beneficially owned after the transaction. The filing notes the 10b5-1 plan was adopted on 08/13/2024 and the Form 4 was signed via attorney-in-fact on 10/08/2025. The transaction is described as executed pursuant to the trading plan.
Insider sale under 10b5-1 plan. An officer of Ionis Pharmaceuticals (IONS), Joseph T. Baroldi, sold 1,625 shares of common stock on 10/06/2025 at a weighted-average price of $69.3693 per share under a Rule 10b5-1 trading plan adopted on 05/02/2025. After the reported sale, Mr. Baroldi directly beneficially owns 30,301 shares and indirectly owns 3,071 shares through his spouse. The filer notes the sale occurred in multiple transactions at prices ranging from $69.36 to $69.41 and offers to provide a price-by-price breakdown on request.
Insider notice to sell common stock: A Form 144 filing shows proposed sale of 437 shares of common stock on 10/06/2025 via Stifel Nicolaus & Company on Nasdaq with an aggregate market value of $30,268.00. The shares were acquired under an Employee Stock Purchase Plan on 09/03/2024 and paid in cash. The filer represents no undisclosed material adverse information and the filing includes prior sales by the same person totaling 208,648 shares across dates in 2025 with gross proceeds shown (largest single prior sale: $12,228,840.00 on 09/03/2025). The notice states standard Rule 144 and Rule 10b5-1 remarks and signature attestation.
Form 144 notice shows a proposed sale of 1,625 common shares by an insider who acquired them as restricted stock units on 04/15/2025. The shares are to be sold through Stifel Nicolaus & Company on 10/06/2025 with an aggregate market value of $112,725.00 based on the filing. The issuer reports 159,391,229 shares outstanding.
The filer disclosed prior insider sales totaling 60,000 shares during the past three months (sales on 09/03/2025, 09/05/2025, 09/09/2025, and 10/02/2025) generating $3,724,770.00 in gross proceeds. The current notice states the securities were paid for in cash at acquisition and were granted by the issuer as RSUs.
Ionis Pharmaceuticals, Inc. filed a Form 144 notice reporting a proposed sale of 6,849 shares of common stock, with an aggregate market value of $472,718, to be executed approximately on 10/06/2025 through Stifel Nicolaus & Company on Nasdaq. The shares were acquired as Restricted Stock Units from the issuer on 01/15/2025 and paid for in cash on the same date. The filer reports total shares outstanding of 159,391,229. The notice also lists three prior sales by the same person, Eric Swayze, totaling 38,244 shares sold on 09/02/2025, 10/01/2025, and 10/02/2025, generating combined gross proceeds of $2,346,609. The signer affirms no undisclosed material adverse information and references Rule 10b5-1 conditions.
IONIS PHARMACEUTICALS, INC. (IONS) Rule 144 notice reports a proposed sale of 22,400 shares of common stock through Goldman Sachs & Co. LLC on 10/01/2025, with an aggregate market value of $1,473,920. The filing lists total shares outstanding of 159,391,229. The securities were acquired on multiple dates by the reporting party (option exercise and restricted stock units), including notable lots: 3,560 shares (09/16/2020), 6,394 shares (07/17/2018), 5,300 shares (02/14/2014) and 4,677 shares (07/15/2024). The filing also discloses related sales by the Joseph H. Wender Trust totaling 33,600 shares in Sep–Oct 2025 for gross proceeds of approximately $1.98 million. Other issuer identification fields are blank in the form content provided.
Patrick R. O'Neil, Executive Vice President, Chief Legal Officer & General Counsel of Ionis Pharmaceuticals (IONS), reported option exercises and subsequent sales on September 29-30, 2025. The Form 4 shows Mr. O'Neil acquired 10,473 shares on 09/29/2025 and 14,827 shares on 09/30/2025 via exercise of non-qualified stock options with an exercise price of $56.78 per share. On the same dates he sold the exercised shares: 10,473 shares on 09/29/2025 at a weighted average price of $64.5417, and 14,827 shares on 09/30/2025 at a weighted average price of $64.6777. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted May 2, 2025. Following these transactions, Mr. O'Neil beneficially owned 57,130 shares.
Richard S. Geary, EVP & Chief Development Officer of Ionis Pharmaceuticals (IONS), reported option exercise and share sales on 09/30/2025. He exercised a non-qualified stock option with a $53.77 exercise price to acquire 57,900 shares, increasing his direct beneficial ownership to 137,557 shares. On the same date he sold 57,900 shares under a Rule 10b5-1 trading plan adopted May 6, 2025, for a weighted-average price of $65.2447 per share, with individual sale prices in the $65.00 to $65.52 range. The filing was submitted by an attorney-in-fact.
IONIS PHARMACEUTICALS, INC. (IONS) submitted a Form 144 reporting a proposed sale of 27,114 shares of common stock through Stifel Nicolaus & Company on Nasdaq, with an aggregate market value of $1,789,524 and total shares outstanding reported as 159,391,229. The filer reports acquiring 17,114 of these shares on 01/15/2021 by option exercise, with payment listed as cash and an approximate sale date of 10/01/2025.
The filing also discloses a prior sale by the same person on 09/02/2025 of 11,130 shares for $552,865. By simple proportion, the proposed sale represents approximately 0.017% of outstanding shares, indicating the transaction is small relative to the company's share count. The notice contains the standard insider representation about absence of undisclosed material information.